Manganese(I) tricarbonyl complexes as potential anticancer agents
- PMID: 34713347
- DOI: 10.1007/s00775-021-01910-7
Manganese(I) tricarbonyl complexes as potential anticancer agents
Abstract
The antiproliferative activity of [Mn(CO)3(N^N)Br] (N^N = phendione 1, bipy 3) and of the two newly synthesized Mn complexes [Mn(CO)3(acridine)(phendione)]OTf (2) and [Mn(CO)3(di-triazole)Br] (4) has been evaluated by MTS against three tumor cell lines A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), HCT116doxR (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The antiproliferative assay showed a dose-dependent effect higher in complex 1 and 2 with a selectivity toward ovarian carcinoma cell line 21 times higher than in human fibroblasts. Exposure of A2780 cells to IC50 concentrations of complex 1 and 2 led to an increase of reactive oxygen species that led to the activation of cell death mechanisms, namely via intrinsic apoptosis for 2 and autophagy and extrinsic apoptosis for 1. Both complexes do not target DNA or interfere with cell cycle progression but are able to potentiate cell migration and neovascularization (for 2) an indicative that their application might be directed for initial tumor stages to avoid tumor invasion and metastization and opening a new avenue for complex 2 application in regenerative medicine. Interestingly, both complexes do not show toxicity in both in vivo models (CAM and zebrafish).
Keywords: A2780 tumor cells; Antiproliferative activity; Cancer; In vivo models; Mn(I) complexes.
© 2021. The Author(s), under exclusive licence to Society for Biological Inorganic Chemistry (SBIC).
References
-
- Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 - DOI - PubMed - PMC
-
- Abbas Z, Rehman S (2018) An overview of cancer treatment modalities. In: Neoplasm. INTECH. https://doi.org/10.5772/intechopen.76558 - DOI
-
- Makovec T (2019) Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 53:148–158. https://doi.org/10.2478/raon-2019-0018 - DOI - PubMed - PMC
-
- Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. https://doi.org/10.1016/j.ejphar.2014.07.025 - DOI - PubMed - PMC
-
- Kostova I (2006) Ruthenium complexes as anticancer agents. Curr Med Chem 13:1085–1107. https://doi.org/10.2174/092986706776360941 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical